Rejection of adenovirus infection is independent of coxsackie and adenovirus receptor expression in cisplatin-resistant human lung cancer cells

Zhang,Nian-Hua; Peng,Rui-Qing; Ding,Ya; Zhang,Xiao-Shi

doi:10.3892/or.2016.4870

Rejection of adenovirus infection is independent of coxsackie and adenovirus receptor expression in cisplatin-resistant human lung cancer cells

Authors:
- Nian-Hua Zhang
- Rui-Qing Peng
- Ya Ding
- Xiao-Shi Zhang
View Affiliations

Affiliations: Department of Oncology, Guangdong Second Provincial Traditional Chinese Medicine Hospital, Guangzhou, Guangdong 510095, P.R. China, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China
Published online on: June 13, 2016 https://doi.org/10.3892/or.2016.4870
Pages: 715-720

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The adenovirus vector-based cancer gene therapy is controversial. Low transduction efficacy is believed to be one of the main barriers for the decreased expression of coxsackie and adenovirus receptor (CAR) on tumor cells. However, the expression of CAR on primary tumor tissue and tumor tissue survived from treatment has still been not extensively studied. The present study analyzed the adenovirus infection rates and CAR expression in human lung adenocarcinoma cell line A549 and its cisplatin-resistant subline A549/DDP. The results showed that although the CAR expression in A549 and A549/DDP was not different, compared with the A549, A549/DDP appeared obviously to reject adenovirus infection. Moreover, we modified CAR expression in the two cell lines with proteasome inhibitor MG-132 and histone deacetylase inhibitor trichostatin A (TSA), and analyzed the adenovirus infection rates after modifying agent treatments. Both TSA and MG-132 pretreatments could increase the CAR expression in the two cell lines, but the drug pretreatments could only make A549 cells more susceptible to adenovirus infectivity.

View Figures

View References

1	Lu S, Yu Y, Chen Z, Ye X, Li Z and Niu X: Maintenance therapy improves survival outcomes in patients with advanced non-small cell lung cancer: A meta-analysis of 14 studies. Lung. 193:805–814. 2015. View Article : Google Scholar : PubMed/NCBI
2	Casadio C, Guarize J, Donghi S, Di Tonno C, Fumagalli C, Vacirca D, Dell'Orto P, De Marinis F, Spaggiari L, Viale G, et al: Molecular testing for targeted therapy in advanced non-small cell lung cancer: Suitability of endobronchial ultrasound trans-bronchial needle aspiration. Am J Clin Pathol. 144:629–634. 2015. View Article : Google Scholar : PubMed/NCBI
3	Zarogoulidis P, Domvri K, Huang H and Zarogoulidis K: Gene therapy for lung cancer malignant pleural effusion: Current and future nano-biotechnology. Transl Lung Cancer Res. 1:234–237. 2012.PubMed/NCBI
4	Cavazzana-Calvo M, Thrasher A and Mavilio F: The future of gene therapy. Nature. 427:779–781. 2004. View Article : Google Scholar : PubMed/NCBI
5	Sharma A, Tandon M, Bangari DS and Mittal SK: Adenoviral vector-based strategies for cancer therapy. Curr Drug Ther. 4:117–138. 2009. View Article : Google Scholar :
6	Toloza EM, Morse MA and Lyerly HK: Gene therapy for lung cancer. J Cell Biochem. 99:1–22. 2006. View Article : Google Scholar : PubMed/NCBI
7	Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, et al: Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 18:609–622. 2000.PubMed/NCBI
8	Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ, Laufman L, Gralla R, Kuball J, Buhl R, et al: Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study. J Clin Oncol. 19:1750–1758. 2001.PubMed/NCBI
9	Schreiber J, Langhorst H, Jüttner R and Rathjen FG: The IgCAMs CAR, BT-IgSF, and CLMP: Structure, function, and diseases. Adv Neurobiol. 8:21–45. 2014. View Article : Google Scholar : PubMed/NCBI
10	Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, Curiel DT and Douglas JT: The therapeutic efficacy of adeno-viral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer. 38:1917–1926. 2002. View Article : Google Scholar : PubMed/NCBI
11	Ma J, Zhao J, Lu J, Jiang Y, Yang H, Li P, Zhao M, Liu K and Dong Z: Coxsackievirus and adenovirus receptor promotes antitumor activity of oncolytic adenovirus H101 in esophageal cancer. Int J Mol Med. 30:1403–1409. 2012.PubMed/NCBI
12	Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP, Wang Z and Hsieh JT: Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy. Cancer Res. 59:325–330. 1999.PubMed/NCBI
13	Pearson AS, Koch PE, Atkinson N, Xiong M, Finberg RW, Roth JA and Fang B: Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin Cancer Res. 5:4208–4213. 1999.
14	Qin M, Chen S, Yu T, Escuadro B, Sharma S and Batra RK: Coxsackievirus adenovirus receptor expression predicts the efficiency of adenoviral gene transfer into non-small cell lung cancer xenografts. Clin Cancer Res. 9:4992–4999. 2003.PubMed/NCBI
15	Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP and Curiel DT: Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res. 63:847–853. 2003.PubMed/NCBI
16	Zhang NH, Song LB, Wu XJ, Li RP, Zeng MS, Zhu XF, Wan DS, Liu Q, Zeng YX and Zhang XS: Proteasome inhibitor MG-132 modifies coxsackie and adenovirus receptor expression in colon cancer cell line lovo. Cell Cycle. 7:925–933. 2008. View Article : Google Scholar : PubMed/NCBI
17	Lee CH, Kasala D, Na Y, Lee MS, Kim SW, Jeong JH and Yun CO: Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression. Biomaterials. 35:5505–5516. 2014. View Article : Google Scholar : PubMed/NCBI
18	Shirakawa T, Sasaki R, Gardner TA, Kao C, Zhang ZJ, Sugimura K, Matsuo M, Kamidono S and Gotoh A: Drug-resistant human bladder-cancer cells are more sensitive to adenovirus-mediated wild-type p53 gene therapy compared to drug-sensitive cells. Int J Cancer. 94:282–289. 2001. View Article : Google Scholar : PubMed/NCBI
19	Ingemarsdotter CK, Tookman LA, Browne A, Pirlo K, Cutts R, Chelela C, Khurrum KF, Leung EY, Dowson S, Webber L, et al: Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. Mol Oncol. 9:791–805. 2015. View Article : Google Scholar : PubMed/NCBI
20	Marchetti A, Buttitta F, Merlo G, Diella F, Pellegrini S, Pepe S, Macchiarini P, Chella A, Angeletti CA, Callahan R, et al: p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res. 53:2846–2851. 1993.PubMed/NCBI
21	Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, et al: Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 91:763–771. 1999. View Article : Google Scholar : PubMed/NCBI
22	Gurnani M, Lipari P, Dell J, Shi B and Nielsen LL: Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother Pharmacol. 44:143–151. 1999. View Article : Google Scholar : PubMed/NCBI
23	Nishizaki M, Meyn RE, Levy LB, Atkinson EN, White RA, Roth JA and Ji L: Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res. 7:2887–2897. 2001.PubMed/NCBI
24	Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, et al: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 9:93–101. 2003.PubMed/NCBI
25	Hasenburg A, Fischer DC, Tong XW, Rojas-Martinez A, Kaufman RH, Ramzy I, Kohlberger P, Orlowska-Volk M, Aguilar-Cordova E and Kieback DG: Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: Expression of coxsackie-adenovirus receptor and integrins alphavbeta3 and alphavbeta5. J Soc Gynecol Investig. 9:174–180. 2002. View Article : Google Scholar : PubMed/NCBI
26	Pong RC, Lai YJ, Chen H, Okegawa T, Frenkel E, Sagalowsky A and Hsieh JT: Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. Cancer Res. 63:8680–8686. 2003.PubMed/NCBI
27	Kitazono M, Goldsmith ME, Aikou T, Bates S and Fojo T: Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res. 61:6328–6330. 2001.PubMed/NCBI
28	Watanabe T, Hioki M, Fujiwara T, Nishizaki M, Kagawa S, Taki M, Kishimoto H, Endo Y, Urata Y, Tanaka N, et al: Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp Cell Res. 312:256–265. 2006.
29	Bieler A, Mantwill K, Dravits T, Bernshausen A, Glockzin G, Köhler-Vargas N, Lage H, Gansbacher B and Holm PS: Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: Histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520. Hum Gene Ther. 17:55–70. 2006. View Article : Google Scholar : PubMed/NCBI
30	El-Zawahry A, Lu P, White SJ and Voelkel-Johnson C: In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-X_L. Cancer Gene Ther. 13:281–289. 2006. View Article : Google Scholar
31	Sasaki Y, Negishi H, Idogawa M, Suzuki H, Mita H, Toyota M, Shinomura Y, Imai K and Tokino T: Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models. Mol Cancer Ther. 7:779–787. 2008. View Article : Google Scholar : PubMed/NCBI
32	Earel JK Jr, VanOosten RL and Griffith TS: Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 66:499–507. 2006. View Article : Google Scholar : PubMed/NCBI
33	Berghauser Pont LM, Kleijn A, Kloezeman JJ, van den Bossche W, Kaufmann JK, de Vrij J, Leenstra S, Dirven CM and Lamfers ML: The HDAC inhibitors scriptaid and LBH589 combined with the oncolytic virus delta24-RGD exert enhanced anti-tumor efficacy in patient-derived glioblastoma cells. PLoS One. 10:e01270582015. View Article : Google Scholar : PubMed/NCBI
34	Kim DR, Park MY, Lim HJ, Park JS, Cho YJ, Lee SW, Yoon HI, Lee JH, Kim YS and Lee CT: Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors. Int J Mol Med. 29:218–224. 2012.
35	MacTavish H, Diallo JS, Huang B, Stanford M, Le Boeuf F, De Silva N, Cox J, Simmons JG, Guimond T, Falls T, et al: Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS One. 5:e144622010. View Article : Google Scholar
36	Vincent T, Pettersson RF, Crystal RG and Leopold PL: Cytokine-mediated downregulation of coxsackievirus-adenovirus receptor in endothelial cells. J Virol. 78:8047–8058. 2004. View Article : Google Scholar : PubMed/NCBI
37	Anders M, Christian C, McMahon M, McCormick F and Korn WM: Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res. 63:2088–2095. 2003.PubMed/NCBI